Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury

Kidney International

Volumn 81, Issue 10, 2012, Pages 983-992

  Lai, Li Wen ^a   Yong, Kim Chong ^a   Lien, Yeong Hau H ^b,c  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Arizona Kidney Disease and Hypertension Center   (United States)

Author keywords

Acute kidney injury; Chemokine; Lymphocytes; Renal ischemia reperfusion; TNF

Indexed keywords

BASILIXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; N,N DIMETHYLSPHINGOSINE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ISCHEMIA; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; REPERFUSION INJURY; SHAM PROCEDURE; UPREGULATION;

EID: 84860368153     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.412     Document Type: Article

References (44)

1. Taams LS, Palmer DB, Akbar AN et al. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006; 118: 1-9.
2. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585-598.
3. Morgan ME, Flierman R, van Duivenvoorde LM et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005; 52: 2212-2221.
4. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170: 3939-3943.
5. Scalapino KJ, Tang Q, Bluestone JA et al. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 2006; 177: 1451-1459.
6. Cohen JL, Trenado A, Vasey D et al. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
7. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485.
8. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-491.
9. Li L, Huang L, Sung SS et al. NKT cell activation mediates neutrophil IFNgamma production and renal ischemia-reperfusion injury. J Immunol 2007; 178: 5899-5911.
10. Lai LW, Yong KC, Igarashi S et al. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int 2007; 71: 1223-1231.
11. Kinsey GR, Sharma R, Huang L et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 2009; 20: 1744-1753.
12. Kinsey GR, Huang L, Vergis AL et al. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010; 77: 771-780.
13. Lee H, Nho D, Chung HS et al. CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int 2010; 78: 1100-1109.
14. Edsall LC, Van Brocklyn JR, Cuvillier O et al. N,N-dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 1998; 37: 12892-12898.
15. Donnahoo KK, Meng X, Ayala A et al. Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemiareperfusion. Am J Physiol 1999; 277: R922-R929.
16. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210.
17. Lien YH, Yong KC, Cho C et al. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 2006; 69: 1601-1608.
18. Huang LS, Kim MR, Sok DE. Oxygenation of 1-docosahexaenoyl lysophosphatidylcholine by lipoxygenases; conjugated hydroperoxydiene and dihydroxytriene derivatives. Lipids 2007; 42: 981-990.
19. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
20. Manzotti CN, Tipping H, Perry LC et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol 2002; 32: 2888-2896.
21. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
22. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
23. Tang Q, Boden EK, Henriksen KJ et al. Distinct roles of CTLA-4 and TGFbeta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34: 2996-3005.
24. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003; 74: 961-965.
25. Setoguchi R, Hori S, Takahashi T et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201: 723-735.
26. Couper KN, Blount DG, de Souza JB et al. Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 2007; 178: 4136-4146.
27. MacKinnon AC, Buckley A, Chilvers ER et al. Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents. J Immunol 2002; 169: 6394-6400.
28. Kohm AP, McMahon JS, Podojil JR et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006; 176: 3301-3305.
29. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9: 970-980.
30. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 2006; 6: 682-692.
31. Yurchenko E, Tritt M, Hay V et al. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 2006; 203: 2451-2460.
32. Muller M, Carter SL, Hofer MJ et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007; 179: 2774-2786.
33. Igarashi Y, Hakomori S, Toyokuni T et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 1989; 28: 6796-6800.
34. Megidish T, White T, Takio K et al. The signal modulator protein 14-3-3 is a target of sphingosine-or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells. Biochem Biophys Res Commun 1995; 216: 739-747.
35. King CC, Zenke FT, Dawson PE et al. Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1. J Biol Chem 2000; 275: 18108-18113.
36. French KJ, Schrecengost RS, Lee BD et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-5969.
37. Vlasenko LP, Melendez AJ. A critical role for sphingosine kinase in anaphylatoxin-induced neutropenia, peritonitis, and cytokine production in vivo. J Immunol 2005; 174: 6456-6461.
38. Kim M, Kim M, Kim N et al. Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate- dependent pathways. Am J Physiol Renal Physiol 2007; 293: F1827-F1835.
39. Jo SK, Bajwa A, Ye H et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int 2009; 75: 167-175.
40. Megidish T, Cooper J, Zhang L et al. A novel sphingosine-dependent protein kinase (SDK1) specifically phosphorylates certain isoforms of 14-3-3 protein. J Biol Chem 1998; 273: 21834-21845.
41. Alfonso A, De la Rosa LA, Vieytes MR et al. Dimethylsphingosine increases cytosolic calcium and intracellular pH in human T lymphocytes. Biochem Pharmacol 2003; 65: 465-478.
42. Gandolfo MT, Jang HR, Bagnasco SM et al. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 2009; 76: 717-729.
43. Gandolfo MT, Jang HR, Bagnasco SM et al. Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. Transpl Immunol 2010; 23: 45-52.
44. Melnikov VY, Ecder T, Fantuzzi G et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001; 107: 1145-1152.